160 related articles for article (PubMed ID: 36455876)
1. A circadian rhythm-related biomarker for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Cheng Y; Yao J; Fang Q; Chen B; Zang G
Aging (Albany NY); 2022 Dec; 14(23):9617-9631. PubMed ID: 36455876
[TBL] [Abstract][Full Text] [Related]
2. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
3. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
Peng X; Wu H; Zhang B; Xu C; Lang J
Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
[TBL] [Abstract][Full Text] [Related]
4. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
5. CD8
Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
Front Immunol; 2022; 13():806877. PubMed ID: 35273597
[TBL] [Abstract][Full Text] [Related]
6. An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms.
Zhang N; Zhang H; Liu Z; Dai Z; Wu W; Zhou R; Li S; Wang Z; Liang X; Wen J; Zhang X; Zhang B; Ouyang S; Zhang J; Luo P; Li X; Cheng Q
Cell Prolif; 2023 Apr; 56(4):e13409. PubMed ID: 36822595
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
8. A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Ou W; Wang SY
Front Immunol; 2023; 14():1147528. PubMed ID: 37033934
[TBL] [Abstract][Full Text] [Related]
9. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
10. Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma.
Sun J; Guo H; Nie Y; Zhou S; Zeng Y; Sun Y
Sci Rep; 2024 Apr; 14(1):9276. PubMed ID: 38653742
[TBL] [Abstract][Full Text] [Related]
11. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma.
Xu F; Zhan X; Zheng X; Xu H; Li Y; Huang X; Lin L; Chen Y
Genomics; 2020 Nov; 112(6):4675-4683. PubMed ID: 32798715
[TBL] [Abstract][Full Text] [Related]
12. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
13. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract][Full Text] [Related]
14. Development of cancer-associated fibroblast-related gene signature for predicting the survival and immunotherapy response in lung adenocarcinoma.
Zhang Y; Cheng F; Ma J; Shi G; Deng H
Aging (Albany NY); 2023 Jun; 15(11):4986-5006. PubMed ID: 37280069
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing.
Song P; Li W; Guo L; Ying J; Gao S; He J
Front Immunol; 2022; 13():850745. PubMed ID: 35757748
[TBL] [Abstract][Full Text] [Related]
16. An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma.
Han T; Liu Y; Wu J; Bai Y; Zhou J; Hu C; Zhang W; Guo J; Wang Q; Hu D
Sci Rep; 2023 Mar; 13(1):5153. PubMed ID: 36991102
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma.
Li C; Yuan Y; Jiang X; Wang Q
Sci Rep; 2023 Aug; 13(1):13568. PubMed ID: 37604869
[TBL] [Abstract][Full Text] [Related]
18. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
19.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
20. LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response.
Huang J; Yuan L; Huang W; Liao L; Zhu X; Wang X; Li J; Liang W; Wu Y; Liu X; Yu D; Zheng Y; Guan J; Zhan Y; Liu L
Front Immunol; 2022; 13():1064874. PubMed ID: 36505456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
